Saturday, November 2nd

line 600x11 px
gap 50x5
gap 20x5
gap 500x5 px
9:00 Session 4 • TARGETED THERAPIES I
Registry data – agalsidase beta
Dominique Germain (FR)
Interpreting effectiveness data in Fabry disease – agalsidase alfa
Christoph Kampmann (DE)
Immune response to enzyme replacement therapies
Malte Lenders (DE)
10:20 COFFEE BREAK
11:00 Session 5 • TARGETED THERAPIES II
Amenability testing
Response to migalastat – enzymatic levels and biomarkers
Peter Nordbeck (DE)
Substrate reduction therapies
Markus Cybulla (DE)
Chaperones
Derralynn Hughes (GB)
New enzymes
David Warnock (US)
Genetic treatments
13:10 LUNCH
14:00 Session 6 • SYMPTOMATIC TREATMENTS
Pain management
Rocco Liguori (IT)
Renin-angiotensin system inhibitors – what can be expected
Alberto Ortiz (ES)
Arrhythmia management and sudden death prevention
Maurizio Pieroni (IT)
Valvular disease – what is known and how to manage them
Aleš Linhart (CZ)
Future trends in AFD
Perry Elliott (GB)
15:40 Closing remarks and adjourn
line 600x11 px
Organized under the auspices of the Czech Society of Cardiology.

Endorsed by Center for Fabry Disease, General University Hospital Prague, Czech Republic

Endorsed by French Reference Center for Fabry Disease, University of Versailles, France

Copyright © 2013 Galén Symposion, All Rights Reserved
web-mastering People For Net a.s.